Trial Profile
A 6-week, prospective, randomized, double-blind, double-dummy phase IV clinical trial designed to evaluate the efficacy of an aggressive multi-risk factor management strategy with caduet versus a guideline-based approach in achieving blood pressure and lipid goals in hypertensive subjects with additional risk factors
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Feb 2021
Price :
$35
*
At a glance
- Drugs Amlodipine/atorvastatin (Primary) ; Amlodipine
- Indications Dyslipidaemias; Hypertension
- Focus Therapeutic Use
- Acronyms TOGETHER
- Sponsors Pfizer; Viatris Inc
- 09 May 2009 Primary endpoint results presented at the 24th Annual Scientific Meeting of the American Society of Hypertension
- 26 Nov 2008 Actual patient number reported as 245 by ClinicalTrials.gov.
- 18 May 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov